|
Title
|
|
|
|
CD70 : an emerging target in cancer immunotherapy
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Pharmacology and therapeutics. - Oxford
| |
|
Publication
|
|
|
|
Oxford
:
2015
| |
|
ISSN
|
|
|
|
0163-7258
| |
|
DOI
|
|
|
|
10.1016/J.PHARMTHERA.2015.07.007
| |
|
Volume/pages
|
|
|
|
155
(2015)
, p. 1-10
| |
|
ISI
|
|
|
|
000364897500001
| |
|
Pubmed ID
|
|
|
|
26213107
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|